Kisspeptin-10 Benefits and Side Effects: Research Data

What Is Kisspeptin-10?

Kisspeptins are peptides made from the KISS1 gene, first identified as a metastasis suppressor gene. In 2001 two groups isolated them from human placenta as the natural ligands of an orphan receptor, GPR54, now called KISS1R or the kisspeptin receptor: a 54-amino-acid form (also named metastin) and shorter 14- and 13-amino-acid forms, all derived from the same precursor protein and ending in the same RF-amide sequence.^[7][8]

Kisspeptin-10 is the shortest active form: the last ten amino acids that all native kisspeptins share, ending in Arg-Phe-NH₂.^[9] PubChem lists kisspeptin-10 as C₆₃H₈₃N₁₇O₁₄, about 1,302.4 g/mol.^[10] Researchers described it as the minimal sequence with full intrinsic bioactivity.^[1]

How Kisspeptin Works: GnRH Release and the Reproductive Axis

Kisspeptin neurons in the hypothalamus sit at the top of the reproductive hormone cascade, the hypothalamic pituitary gonadal axis. Kisspeptin signals through its receptor on GnRH neurons to stimulate GnRH release; gonadotropin releasing hormone then drives the pituitary to release LH and follicle stimulating hormone (FSH), which act on the testes and ovaries.^[9][11]

Genetics showed how central this kisspeptin signaling is. People with inactivating mutations in GPR54 did not go through puberty (idiopathic hypogonadotropic hypogonadism), and mice lacking the receptor had the same failure of reproductive function, even though they still responded to GnRH and had normal hypothalamic GnRH levels.^[12] Kisspeptin expression extends to the placenta, liver, pancreas, adipose tissue, bone and limbic brain regions, which is why the kisspeptin system is studied in metabolism, energy balance and emotional behavior as well as reproduction.^[9]

Energy Status and the Reproductive Axis

In animal models, kisspeptin integrates metabolic signals, a measure of energy status, with the reproductive axis. That link is why researchers tested whether kisspeptin-10 could restore LH and testosterone in men with type 2 diabetes, described below.^[13] A kisspeptin-54 trial in women with low sexual desire described additional emerging roles for kisspeptin in sexual and emotional behavior.^[4]

Kisspeptin-10 Benefits Studied: What Was Reported

LH and FSH Release and Testosterone Production in Healthy Men

The first human study of kisspeptin-10 gave it to healthy men. Kisspeptins stimulate GnRH and thus gonadotropin secretion, and a single exposure produced an acute LH rise, rapid and dose-dependent, within 30 minutes, although the highest dose tested gave a smaller response than the one below it. Continuous exposure raised mean LH and serum testosterone (from 16.6 to 24.0 nmol/L), and continuous exposure at a lower rate increased LH pulse frequency from 0.7 to 1.0 pulses an hour along with pulse size.^[1]

A Boston study in 13 healthy men found that a single exposure to the kisspeptin decapeptide triggered an immediate LH pulse, larger than natural pulses, and delayed the next natural pulse by about one normal interval. The authors described kisspeptin as the first known agent able to reset the hypothalamic GnRH pulse generator.^[11]

Kisspeptin-10 in Women: The Menstrual Cycle and Kisspeptin Levels

Responses in women are not the same. In a London study, kisspeptin-10 raised LH and FSH in healthy men but caused no change in women during the follicular phase of the menstrual cycle, even at the highest levels tested; in the preovulatory phase it did raise LH and FSH.^[2] A study of 31 women found LH pulses after kisspeptin in all women in the luteal and preovulatory phases, but unambiguous responses in only half of those in the early follicular phase, and no resetting of the pulse generator as seen in men. The authors suggested that endogenous kisspeptin levels, or kisspeptin tone, are higher in the early follicular phase.^[14] In the same London study, subcutaneous administration in follicular-phase women also left gonadotropin secretion unchanged.^[2]

Hypogonadism and Hormonal Balance: Small Proof-of-Concept Studies

In five men with type 2 diabetes and low testosterone, kisspeptin-10 raised LH, LH pulse frequency and testosterone (from 8.5 to 11.4 nmol/L) during continuous exposure.^[13] In patients whose puberty failed because of mutations in the neurokinin B system, continuous kisspeptin exposure restored pulsatile secretion of luteinizing hormone.^[15] Both studies were very small and short, and neither tested a clinical outcome such as fertility or symptoms.

Human Clinical Trials of Kisspeptin Administration: Fertility Treatments and Sexual Desire

The larger clinical evidence for kisspeptin comes from kisspeptin-54, the longer form, and should not be read as kisspeptin-10 data. Kisspeptin-10 has a much shorter half-life, about 3 minutes against 28 minutes for kisspeptin-54 in the figures cited by a 2024 Endocrine Reviews summary from Imperial College London.^[9] The same review notes that in women with hypothalamic amenorrhea, repeated kisspeptin-54 led to a reduced LH response within a few days, an example of desensitisation with repeated dosing.^[9]

• IVF, 2014. In 53 women undergoing in vitro fertilization, a single exposure to kisspeptin-54 induced egg maturation; embryos were transferred in 92%, with a clinical pregnancy rate of 23%.^[3]
• IVF in women at high risk of ovarian hyperstimulation, 2017. In a phase 2 randomized trial of 62 women, a second kisspeptin-54 exposure raised the share reaching the target egg yield from 45% to 71%.^[16]
• Low sexual desire in women, 2022. In a crossover trial in premenopausal women with hypoactive sexual desire disorder (32 completers), kisspeptin-54 changed sexual and attraction brain processing on fMRI and was well tolerated with no reported adverse effects.^[4]
• Low sexual desire in men, 2023. In 32 men with the same disorder, kisspeptin-54 modulated brain activity in response to sexual stimuli and increased penile tumescence compared with placebo; sexual desire and arousal were secondary measures.^[17]

A 2026 review of 76 studies in sexual medicine concluded that kisspeptin shows early promise but remains investigational.^[18] A ClinicalTrials.gov search for kisspeptin-10 returned five registered studies, three completed and two withdrawn, all physiology studies rather than approval trials.^[19]

Kisspeptin-10 Side Effects and Safety

• Limited human safety data. FDA states that it has no, or only limited, safety information for the proposed routes of administration of kisspeptin-10, and therefore lacks sufficient information to know whether it would cause harm in humans.^[5]
• Immunogenicity and impurities. FDA lists a possible risk of immune reactions for certain routes, along with complexities over peptide-related impurities and characterization of the active ingredient.^[5]
• Tachyphylaxis. The kisspeptin receptor loses responsiveness after repeated doses or continuous high doses, and in one study the highest kisspeptin-10 bolus gave a smaller LH rise than a lower one.^[9][1]
• Short studies only. Human kisspeptin-10 studies were acute physiology experiments in small groups; none measured long-term adverse effects.^[1][2][13]

The absence of reported side effects in short physiology studies is not evidence of long-term safety.

Regulatory Status of Kisspeptin-10

Kisspeptin-10 vs HCG and Gonadorelin

Kisspeptin acts one step above gonadorelin. WADA’s list describes gonadorelin as gonadotrophin-releasing hormone (GnRH) itself, while kisspeptin regulates the GnRH neurons that release it.^[6][9] Gonadorelin was once FDA-approved but is no longer manufactured, while kisspeptin remains investigational.^[18] Because the GnRH neurons still have to respond, the effect depends on the state of the reproductive axis, as the menstrual-cycle studies show.^[2][14] For the full comparison, read HCG vs gonadorelin vs kisspeptin and the HCG research review. For other peptides studied in low sexual desire, see the PT-141 melanocortin review.

What Kisspeptin-10 Research Does Not Yet Show

• Clinical benefit. No trial has shown that kisspeptin-10 improves fertility outcomes, symptoms of low testosterone or any other clinical endpoint.^[19][18]
• Sustained effects. Studies lasted hours to a day, and the receptor is prone to desensitisation with continuous exposure.^[1][9]
• Transfer from kisspeptin-54. IVF and sexual-desire results were obtained with kisspeptin-54, which lasts longer in the blood.^[3][4][9]

These gaps are not arguments against kisspeptin research. They are arguments against overselling it.

Kisspeptin for Laboratory Research

Remy Research supplies kisspeptin as a research peptide for in-vitro laboratory research settings, as the Genovare Kisspeptin 25mg AQ pen. Each product page carries its specification and batch testing details.